XML 75 R61.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Detail) - Collaboration and License Agreement - Tyvaso DPI - USD ($)
$ in Millions
Aug. 12, 2021
Aug. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Total anticipated cash flows $ 221.5 $ 221.5
R&D Services and License | Over Time    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Allocation [1],[2] $ 6.0  
Progress Measure [2] Ratably  
Recognition Period [2],[3] Aug 2021 - Oct 2021  
Next-Gen R&D Services | Over Time    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Allocation [1] $ 8.8  
Progress Measure Input  
Recognition Period [4] % of completion of costs  
Manufacturing Services | Point In Time    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Allocation [1] $ 206.7  
Recognition Period [5] Transfer of control  
[1]

Allocation is based on management’s assessment of the stand-alone selling price of each performance obligation.
[2]

The license for the Company’s IP was considered to be interdependent with the development activities to support approval of Tyvaso DPI. A sales-based royalty is promised in exchange for the IP license; therefore, the royalties associated with the license are excluded from the determination of the transaction price and the Company will recognize revenue as the sale of Tyvaso DPI to a patient occurs.

[3]

Represents the estimated period when the R&D Services performance obligation will be substantially complete.
[4]

The Next-Gen R&D Services performance obligation will be satisfied over time using the input method based on the costs incurred to date as a percentage of the total estimated costs to fulfill the contract. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer.
[5]

The Manufacturing Services performance obligation will be recognized as control of manufactured products is transferred to the customer; therefore, no revenue associated with this obligation was recognized during the three or nine months ended September 30, 2021. The allocation of transaction price is based on the Company’s estimated production and the ultimate cash flows may vary as manufacturing purchase orders are received.